MARKET

MRNA

MRNA

Moderna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

349.15
+20.65
+6.29%
Opening 15:49 07/28 EDT
OPEN
332.92
PREV CLOSE
328.50
HIGH
350.99
LOW
327.52
VOLUME
11.89M
TURNOVER
--
52 WEEK HIGH
362.00
52 WEEK LOW
54.21
MARKET CAP
140.19B
P/E (TTM)
278.38
1D
5D
1M
3M
1Y
5Y
Why Moderna Shares Are Surging Today
Moderna Inc (NASDAQ: MRNA) shares are trading higher by 6.2% at $348.47, rebounding after the stock dipped on Tuesday amid vaccine supply concerns. Vaccine stocks have also gained recently amid COVID-19 Delta variant concerns.
Benzinga · 6m ago
BRIEF-U.S. CDC Says Administered 343.4 Million Doses Of Covid-19 Vaccine As Of July 28
reuters.com · 47m ago
WHO Is Currently Not In Favor Of COVID Booster Shots Citing Lack Of Data: CNBC
Benzinga · 2h ago
WHO doesn’t recommend Covid booster doses right now, citing lack of data
The WHO said it would not yet endorse booster shots on Wednesday, citing a lack of data on the efficacy of an extra vaccine dose in protecting against variants.
CNBC.com · 5h ago
Dyadic Int'l (DYAI) Inks Deal Toward Potential Access to 40% of the World as Covid Vaccine Continues in Development
WallStreetPR · 7h ago
UPDATE 5-Pfizer says 2021 COVID-19 vaccine sales to top $33.5 bln, sees need for boosters
reuters.com · 8h ago
UPDATE 4-Pfizer raises 2021 COVID-19 vaccine sales forecast to $33.5 billion
reuters.com · 8h ago
UPDATE 2-Thermo Fisher profit beats estimates on COVID-19 services demand
reuters.com · 9h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNA. Analyze the recent business situations of Moderna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNA stock price target is 195.93 with a high estimate of 299.00 and a low estimate of 83.00.
EPS
Institutional Holdings
Institutions: 862
Institutional Holdings: 210.87M
% Owned: 52.52%
Shares Outstanding: 401.53M
TypeInstitutionsShares
Increased
284
36.57M
New
166
5.17M
Decreased
218
29.60M
Sold Out
98
1.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.46%
Pharmaceuticals & Medical Research
+2.06%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Noubar Afeyan
President
Stephen Hoge
Chief Executive Officer/Director
Stephane Bancel
Chief Financial Officer
David Meline
Chief Human Resource Officer
Tracey Franklin
Chief Technology Officer
Juan Andres
General Counsel/Secretary
Lori Henderson
Other
Marcello Damiani
Other
Ray Jordan
Other
Corinne Le Goff
Other
Jose Vega
Other
Tal Zvi Zaks
Secretary
Shannon Klinger
Independent Director
Stephen Berenson
Independent Director
Sandra Horning
Independent Director
Robert Langer
Independent Director
Elizabeth Nabel
Independent Director
Francois Nader
Independent Director
Paul Sagan
Independent Director
Elizabeth Tallett
No Data
About MRNA
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Webull offers kinds of Moderna Inc stock information, including NASDAQ:MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.